Investment Rating - The report assigns an "Accumulate" rating for the company, indicating a positive outlook based on its growth potential in the precision motion control solutions sector [5]. Core Insights - The company specializes in customized precision motion control solutions, benefiting from the anticipated acceleration of the humanoid robot industry. In Q1 2025, the company's net profit attributable to shareholders increased by 136% year-on-year [5]. - The company has established a long-term strategic partnership with Mindray Medical, focusing on domestic substitution in the medical equipment sector, which is supported by favorable policies [5]. - The humanoid robot sector is seeing active product platform development, with the company making significant advancements in core technologies [5][6]. Financial Performance - In 2024, the company is projected to achieve revenue of 224 million yuan, with a net profit of 39 million yuan. For Q1 2025, revenue reached 59 million yuan, reflecting a year-on-year growth of 35.76% [5]. - The company forecasts revenues of 265 million yuan in 2025, with a net profit of 46 million yuan, and expects continued growth in subsequent years [7][8]. Strategic Initiatives - The company has launched a stock incentive plan to motivate its core team, reflecting confidence in its growth trajectory [5]. - It is actively expanding its product offerings in the medical device sector and humanoid robotics, with ongoing collaborations with various industry players [5][8]. - The company is investing in new manufacturing facilities and establishing a global marketing network to enhance supply chain security and support business growth [8].

Core Viewpoint - Jiangsu Leili is advancing its layout in the humanoid robot sector while maintaining strong growth in its core micro motor and component business, despite a slight decline in net profit in 2024 [1][2]. Financial Performance - In 2024, the company achieved revenue of 3.519 billion yuan, a year-on-year increase of 14.38%, while net profit attributable to shareholders was 294 million yuan, a decrease of 7.14%. The net profit excluding non-recurring items was 301 million yuan, an increase of 3.53% [1]. - In Q1 2025, the company reported revenue of 908 million yuan, a year-on-year increase of 25.81%, and net profit attributable to shareholders of 94 million yuan, up 28.15% [1]. Product Development and Innovation - Jiangsu Leili has adopted an "Electric Motor+" strategy, expanding its product offerings to include precision gearboxes, sensors, and drive control systems, with several new products entering mass production in non-home appliance sectors in 2024 [1][2]. - The company has developed a comprehensive motion control system solution for humanoid robots, including linear joints, rotary joints, and dexterous hands, and is focusing on high-precision sensors and control components through external investments and collaborations [2][3]. Strategic Partnerships - Jiangsu Leili has established a partnership with Blue Technology, a leading quadruped robot company in China, to supply joint actuators for quadruped robots and enhance resource integration for product development and cost reduction [3]. Global Expansion and Market Strategy - The company is enhancing its overseas production capacity and sales network to mitigate the impact of U.S.-China trade tensions, with approximately 18% of its revenue coming from the U.S. market in 2024 [4]. - Jiangsu Leili has established R&D and manufacturing bases in North America, Europe, Southeast Asia, South Korea, and Hong Kong, with a completed expansion of its Vietnam factory and a new factory in Mexico set to begin production in 2025 [4].

Group 1: Company Performance - Changyuan Donggu achieved a net profit of 230 million in 2024, a year-on-year increase of 5%[1] - In Q4 2024, the company reported a net profit of 75 million, a significant year-on-year increase of 292%[1] - For Q1 2025, the net profit continued to grow, reaching 78 million, up 66% year-on-year[1] Group 2: Market Overview - The ChiNext Index rose by 1.38% last week, while the Shanghai Composite Index increased by 0.76%[3] - The small-cap index experienced a slight decline of 0.02% during the same period[3] - The overall net increase and decrease in shares amounted to -5.188 billion, with 46 companies increasing and 143 companies decreasing their holdings[32] Group 3: Corporate Actions - One company, Sunshine Nuohuo, announced a merger and acquisition plan last week[18] - Two companies, Tangyuan Electric and Wangli Security, released project-based fundraising plans[19] - Nine companies, including Fengguang Precision and Jidong Cement, announced equity incentive plans[21]

证券代码：873593 证券简称：鼎智科技 公告编号：2025-070 江苏鼎智智能控制科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 江苏鼎智智能控制科技股份有限公司 2024 年年度权益分派方案已获 2025 年 5 月 13 日召开的股东会审议通过，本次实施分配方案距离股东会审议通过的 时间未超过两个月。 现将权益分派事宜公告如下： 本次权益分派基准日合并报表归属于母公司的未分配利润为 112,696,418.75 元，母公司未分配利润为 117,829,144.81 元，母公司资本公积为 390,684,758.91 元（其中股票发行溢价形成的资本公积为 361,657,072.06 元，其他资本公积为 29,027,686.85 元）。本次权益分派共计转增 53,784,683 股，派发现金红利 26,892,341.80 元。 一、权益分派方案 1、本公司 2024 年年度权益分派方案为： 以公司现有总股本 134,461,709 股为基数 ...

证券代码：873593 证券简称：鼎智科技 公告编号：2025-069 委托理财进展的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 江苏鼎智智能控制科技股份有限公司 一、 授权委托理财情况 公司于 2025 年 1 月 7 日召开第二届董事会第十次会议、2025 年 1 月 22 日 召开 2025 年第一次临时股东大会，审议通过《关于使用闲置自有资金购买理财 产品的议案》。根据公司目前资金使用情况，在不影响公司主营业务正常发展并 确保公司经营需求的前提下，在授权额度内使用部分闲置自有资金购买理财产 品，以提高公司闲置资金的使用效率和效果，投资额度单笔不超过 5,000 万元， 一个会计年度内任意一个时间点同时持有多笔金额不超过 35,000 万元的闲置自 有资金进行中短期中低风险理财。在上述额度内，资金可以滚动使用，理财取得 的收益可进行再投资,再投资的金额不包含在上述额度以内。具体内容详见公司 于 2025 年 1 月 7 日在北京证券交易所官方信息披露平台(www.bse.cn)上披露的 ...

Group 1 - The core viewpoint of the article highlights the rise of Mindray Medical as a symbol of the Shenzhen medical device industry's transformation from non-existence to a global leader in medical devices and solutions [1] - Mindray Medical has significantly impacted the supply chain by promoting the localization of core components, with over 80% of its first-tier suppliers being domestic, and collaborating with more than 1,500 suppliers across various sectors [1] - During the surge in demand for ventilators in 2020, Mindray Medical increased its procurement of domestic components and worked closely with suppliers to enhance production capacity and establish quality control standards [1] Group 2 - Mindray Medical is driving the high-end standardization of domestic medical devices, with a reputation for rigorous quality testing, which has elevated the quality control standards across the industry [2] - The company's products are now available in over 190 countries, with a market share in the top three for key products like monitors, anesthesia machines, and ventilators, and international revenue contributing approximately 45% of total income [2] - Mindray Medical's internationalization strategy includes utilizing local talent, with nearly 80% of overseas key employees required to regularly visit the Shenzhen headquarters for knowledge exchange [3] Group 3 - The company has established a robust overseas talent management system, integrating local knowledge with its corporate culture to enhance cohesion and operational effectiveness [3] - Over 90% of Mindray Medical's 3,000 overseas employees are local hires, demonstrating the company's commitment to local integration in global markets [3]

江苏鼎智智能控制科技股份有限公司 章程 证券代码：873593 证券简称：鼎智科技 公告编号：2025-068 二 0 二五年五月 | | 总则 1 | | --- | --- | | 第一章 | 经营宗旨和范围 2 | | 第二章 | 股份 2 | | 第一节 | 股份发行 2 | | 第二节 | 股份增减和回购 4 | | 第三节 | 股份转让 5 | | 第三章 | 股东和股东大会 6 | | 第一节 | 股东 6 | | 第二节 | 股东大会的一般规定 9 | | 第三节 | 股东大会的召集 14 | | 第四节 | 股东大会的提案与通知 16 | | 第五节 | 股东大会的召开 17 | | 第六节 | 股东大会的表决和决议 21 | | 第四章 | 董事会 29 | | 第一节 | 董事 29 | | 第二节 | 董事会 32 | | 第三节 | 独立董事 38 | | 第五章 | 总经理及其他高级管理人员 44 | | 第六章 | 监事会 47 | | 第一节 | 监事 47 | | 第二节 | 监事会 47 | | --- | --- | | 第七章 | 财务会计制度、利润分配和审计 50 | ...

北京德恒（杭州）律师事务所 关于江苏鼎智智能控制科技股份有限公司 2024 年年度股东会的 法律意见书 杭州市上城区新业路 200 号华峰国际商务大厦 10-11 楼 邮编：310016 电话：(+86)0571-86508080 传真：(+86)0571-87357755 北京德恒（杭州）律师事务所 关于江苏鼎智智能控制科技股份有限公司 2024 年年度股东会的法律意见书 北京德恒（杭州）律师事务所 关于江苏鼎智智能控制科技股份有限公司 2024年年度股东会的 法律意见书 德恒【杭】书（2025）第05042号 致：江苏鼎智智能控制科技股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）《中华人民共和 国公司法》（以下简称"《公司法》"）等法律、法规和规范性文件及《江苏鼎智 智能控制科技股份有限公司章程》（以下简称"《公司章程》"）的规定，北京 德恒（杭州）律师事务所（以下简称"本所"）接受江苏鼎智智能控制科技股份有 限公司（以下简称"鼎智科技"或"公司"）的委托，指派律师参加鼎智科技 2024 年年度股东会，并出具本法律意见书。 公司已向本所保证，公司已向本所披露一切足以影响本法律意见书出 ...

江苏鼎智智能控制科技股份有限公司 证券代码：873593 证券简称：鼎智科技 公告编号：2025-067 2024 年年度股东会决议公告 一、会议召开和出席情况 本次会议的召集与召开符合《中华人民共和国公司法》及有关法律、法规和 《公司章程》的规定。 （二）会议出席情况 出席和授权出席本次股东会的股东共 9 人，持有表决权的股份总数 77,660,338 股，占公司有表决权股份总数的 57.7565%。 3.会议召开方式：现场投票和网络投票相结合方式 4.会议召集人：董事会 5.会议主持人：董事长华荣伟先生 6.召开情况合法合规的说明： （一）会议召开情况 1.会议召开时间：2025 年 5 月 13 日 2.会议召开地点：鼎智科技三楼会议室一 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 4.公司高级管理人员列席会议。 其中通过网络投票参与本次股东会的股东共 2 人，持有表决权的股份总数 846,340 股，占公司有表决权股份总数的 0.6294%。 （三）公司董事、监事、高级管理人员出席或列席股东 ...

执业证书编号：S0230523110001 邮箱：yangy@hlzq.com 证券研究报告 人形机器人 报告日期：2025 年 05 月 12 日 华为哈勃入股千寻智能，大厂加速人形机器人布局 ——人形机器人行业专题研究周报 华龙证券研究所 执业证书编号：S0230124020003 邮箱：lihy@hlzq.com 相关阅读 《整机&零部件&应用场景，车企多环节 布局机器人赛道—人形机器人行业专题 研究周报》2025.04.14 《应用端逐步落地，短期调整不改长期 趋势—人形机器人专题周报》2025.03.24 《智元推出通用具身大模型，重视人形 机器人大脑发展—人形机器人行业专题 研究周报》2025.03.11 请认真阅读文后免责条款 摘要： 5 . 投资评级：推荐（维持） 最近一年走势 行情回顾：2025 年 5 月 6 日至 2025 年 5 月 9 日，人形机器人指 数涨跌幅+2.63%。同期沪深 300 涨跌幅+2.00%，上证综指涨跌幅 +1.92%，深证成指涨跌幅+2.29%，创业板指涨跌幅+3.27%，科创 50 涨跌幅-0.60%。 分析师：杨阳 美的人形机器人进厂，单台可替代 3 名熟 ...